XGExagen Inc. XGN · NASDAQ
$7.27 -2.81% (-$0.21)
- Market cap
- $181.2M
- Enterprise value
- $182.2M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 2.5x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -34.1%
- Gross margin
- 58.6%
- Net margin
- -26.6%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 2.12
- Free float
- 59.4%
About the company
Exagen Inc. (XGN) is a biotechnology company focused on developing and commercializing diagnostic tests for autoimmune diseases. Their main product is the VeraStrat test, which assists physicians in deciding on appropriate treatment for patients with lung cancer. Exagen Inc. is known for its innovative approach to developing diagnostic tools and efforts to bring improvements in the treatment of autoimmune diseases. Exagen Inc. (XGN) shares could be suitable for investors who are tracking the biotechnology sector and seeking investment opportunities in the field of autoimmune disease diagnostics and treatment.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
John Aballi
Employees
216
Headquarters
Vista
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number